SG11202004545XA - Adeno-associated virus variant capsids and use for inhibiting angiogenesis - Google Patents

Adeno-associated virus variant capsids and use for inhibiting angiogenesis

Info

Publication number
SG11202004545XA
SG11202004545XA SG11202004545XA SG11202004545XA SG11202004545XA SG 11202004545X A SG11202004545X A SG 11202004545XA SG 11202004545X A SG11202004545X A SG 11202004545XA SG 11202004545X A SG11202004545X A SG 11202004545XA SG 11202004545X A SG11202004545X A SG 11202004545XA
Authority
SG
Singapore
Prior art keywords
adeno
associated virus
inhibiting angiogenesis
virus variant
variant capsids
Prior art date
Application number
SG11202004545XA
Other languages
English (en)
Inventor
David Kirn
Melissa Kotterman
David Schaffer
Paul Szymanski
Peter Francis
Original Assignee
4D Molecular Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4D Molecular Therapeutics Inc filed Critical 4D Molecular Therapeutics Inc
Publication of SG11202004545XA publication Critical patent/SG11202004545XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202004545XA 2017-11-27 2018-11-26 Adeno-associated virus variant capsids and use for inhibiting angiogenesis SG11202004545XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762590976P 2017-11-27 2017-11-27
US201862664726P 2018-04-30 2018-04-30
PCT/US2018/062478 WO2019104279A1 (en) 2017-11-27 2018-11-26 Adeno-associated virus variant capsids and use for inhibiting angiogenesis

Publications (1)

Publication Number Publication Date
SG11202004545XA true SG11202004545XA (en) 2020-06-29

Family

ID=66631726

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004545XA SG11202004545XA (en) 2017-11-27 2018-11-26 Adeno-associated virus variant capsids and use for inhibiting angiogenesis

Country Status (21)

Country Link
US (1) US11766489B2 (de)
EP (3) EP3717636B1 (de)
JP (3) JP7184894B2 (de)
KR (1) KR20200088853A (de)
CN (1) CN111770999A (de)
AU (2) AU2018372235B9 (de)
BR (1) BR112020010674A2 (de)
CA (1) CA3083472A1 (de)
CL (1) CL2020001360A1 (de)
CR (1) CR20200282A (de)
DK (1) DK3717636T3 (de)
ES (1) ES2946747T3 (de)
FI (1) FI3717636T3 (de)
IL (1) IL274712A (de)
MX (1) MX2020005451A (de)
PE (1) PE20210915A1 (de)
PH (1) PH12020550706A1 (de)
PT (1) PT3717636T (de)
SG (1) SG11202004545XA (de)
UA (1) UA127831C2 (de)
WO (1) WO2019104279A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
US20210071149A1 (en) * 2017-12-19 2021-03-11 Akouos, Inc. Aav-mediated delivery of therapeutic antibodies to the inner ear
CN112368391A (zh) 2018-05-11 2021-02-12 马萨诸塞眼科耳科诊所 腺相关病毒的肝脏特异性嗜性
JP2022502046A (ja) 2018-09-26 2022-01-11 カリフォルニア インスティテュート オブ テクノロジー 標的遺伝子療法のためのアデノ随伴ウイルス組成物
EP4028058A4 (de) * 2019-09-09 2023-09-27 The Regents of the University of California Zusammensetzungen und verfahren zur herstellung und verwendung von multispezifischen antikörpern
BR112022004183A2 (pt) * 2019-09-09 2022-05-31 Massachusetts Eye & Ear Infirmary Métodos e composições para modular a interação entre vírus adeno-associado (aav) e receptor de aav (aavr) para biodistribuição alterada de aav
EP4041312A4 (de) 2019-10-10 2023-12-20 Kodiak Sciences Inc. Verfahren zur behandlung einer augenstörung
AU2020373326A1 (en) * 2019-10-31 2022-06-02 Medizinische Hochschule Hannover AAV vector variants for ocular gene delivery
WO2022126188A1 (en) * 2020-12-16 2022-06-23 Children's Medical Research Institute Aav capsids and vectors
AU2021401998A1 (en) * 2020-12-16 2023-08-03 Children's Medical Research Institute Adeno-associated virus capsids and vectors
CN113041360A (zh) * 2021-04-01 2021-06-29 深圳廷美奥生物技术有限公司 一种用于治疗年龄相关性黄斑变性的药物
BR112023020490A2 (pt) * 2021-04-09 2023-11-21 Avirmax Biopharma Inc Composições e métodos para expressão de transgenes oculares
EP4326339A2 (de) 2021-04-20 2024-02-28 Institut National de la Santé et de la Recherche Médicale (INSERM) Zusammensetzungen und verfahren zur behandlung von degenerativen netzhauterkrankungen
JP2024519888A (ja) * 2021-05-28 2024-05-21 上海瑞宏迪医薬有限公司 カプシド変異を有する組換えアデノ随伴ウイルス及びその応用
CN113481237A (zh) * 2021-06-29 2021-10-08 厦门朔望医药科技有限公司 一种预防和治疗新生血管眼部疾病的基因药物
CN115997012B (zh) * 2021-09-06 2024-03-08 辉大(上海)生物科技有限公司 Rpe65相关眼睛疾病和障碍的治疗
CN114057840B (zh) * 2021-10-14 2022-09-20 和元生物技术（上海）股份有限公司 包含变异的aav9衣壳蛋白的重组腺相关病毒颗粒
WO2023089151A1 (en) * 2021-11-19 2023-05-25 The University Of Bristol Materials and methods for treatment of macular degeneration
CN116444626A (zh) * 2021-12-28 2023-07-18 成都弘基生物科技有限公司 经过修饰的aav衣壳蛋白及其用途
WO2023173086A1 (en) * 2022-03-11 2023-09-14 Avirmax Biopharma Inc. Compositions and methods for expressing therapeutics
CN117180455A (zh) * 2022-06-07 2023-12-08 成都弘基生物科技有限公司 腺相关病毒药物组合物及其用途
WO2024084075A1 (en) 2022-10-20 2024-04-25 Sparingvision Compositions and methods for treating retinal degenerative disorders
CN115838399B (zh) * 2022-12-08 2023-08-11 广州派真生物技术有限公司 腺相关病毒突变体及其应用
CN117247434B (zh) * 2023-11-10 2024-02-02 上海朗昇生物科技有限公司 衣壳修饰型病毒载体及其制备和用途

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US608200A (en) 1898-08-02 Toy cannon
US20030215422A1 (en) 1996-09-11 2003-11-20 John A. Chiorini Aav4 vector and uses thereof
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US7323179B2 (en) 1997-12-19 2008-01-29 Naomi Balaban Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6984517B1 (en) 1998-05-28 2006-01-10 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector and uses thereof
JP4060531B2 (ja) 1998-05-28 2008-03-12 アメリカ合衆国 Ａａｖ５ベクターおよびその使用
CA2349838C (en) 1998-11-05 2011-06-07 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US6491907B1 (en) 1998-11-10 2002-12-10 The University Of North Carolina At Chapel Hill Recombinant parvovirus vectors and method of making
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
ATE417928T1 (de) * 1999-06-08 2009-01-15 Regeneron Pharma Vegf-rezeptorchimären zur behandlung von augenkrankheiten, welche durch vaskuläre permeabilität charakterisiert sind.
JP2003516124A (ja) 1999-10-15 2003-05-13 ユニバーシティー オブ マサチューセッツ 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子
ATE450621T2 (de) 2000-03-30 2009-12-15 Whitehead Biomedical Inst Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
AU2001264862B2 (en) 2000-05-23 2006-03-30 University Of Rochester Method of producing herpes simplex virus amplicons, resulting amplicons, and their use
EP1290161B1 (de) 2000-05-30 2011-06-22 Johnson & Johnson Research Pty Limited METHODEN ZUR GENSUPPRESSION MITHILFE VON RNAi VERSTÄRKENDEN FAKTOREN
CA2456008A1 (en) 2000-08-19 2002-02-28 Axordia Limited Stem cell differentiation
WO2002029858A2 (en) 2000-09-29 2002-04-11 Infineon Technologies North America Corp. Deep trench etching method to reduce/eliminate formation of black silicon
ATE405650T1 (de) 2000-12-14 2008-09-15 Genentech Inc Produktion von ganzen antikörpern in prokaryontischen zellen
US7749492B2 (en) 2001-01-05 2010-07-06 Nationwide Children's Hospital, Inc. AAV vectors and methods
US6962815B2 (en) 2001-01-05 2005-11-08 Children's Hopital Inc. AAV2 vectors and methods
US7271002B2 (en) 2001-11-09 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Production of adeno-associated virus in insect cells
EP2338900B1 (de) 2001-11-13 2014-01-01 The Trustees of The University of Pennsylvania Adenoassoziierten Virus (AAV) Cy.5 Sequenzen, diese enthaltende Vektoren und deren Verwendungen
AU2002360291A1 (en) 2001-12-17 2003-06-30 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 8 sequences
PT2573170T (pt) 2001-12-17 2018-03-26 Univ Pennsylvania Sequências de um vírus adenoassociado (aav) de serotipo 9, vetor contendo as mesmas, e suas utilizações
CA2468882C (en) 2001-12-21 2015-09-29 Medigene Ag A library of modified structural genes or capsid modified particles useful for the identification of viral clones with desired cell tropism
WO2003088899A2 (en) 2002-04-05 2003-10-30 The Children's Hospital Of Philadelphia Methods for the production of chimeric adeno-associated virus (aav) vectors, compositions of chimeric aav vectors, and methods of use thereof
AU2003221733A1 (en) 2002-04-17 2003-11-03 University Of Florida Research Foundation, Inc. Improved raav vectors
SI1496944T1 (sl) 2002-05-01 2009-02-28 Univ Florida Izboljšani sistemi ekspresije RAAV za genetsko modifikacijo specifičnih kapsidnih proteinov
US20040023390A1 (en) 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
US7220577B2 (en) 2002-08-28 2007-05-22 University Of Florida Research Foundation, Inc. Modified AAV
US7186522B2 (en) 2003-03-31 2007-03-06 Cytyc Corporation Papanicolau staining process
US20060286545A1 (en) 2003-05-23 2006-12-21 Mount Sinai School Of Medicine Of New York University Viral vectors with improved properties
EP1486567A1 (de) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verbesserter Adeno-assoziierter Virus (AAV)-Vektor für Gentherapie
US8071028B2 (en) 2003-06-12 2011-12-06 Abbott Diabetes Care Inc. Method and apparatus for providing power management in data communication systems
SI2657248T1 (sl) 2003-06-19 2017-07-31 Genzyme Corporation AAV virioni z zmanjšano imunoreaktivnostjo in njihova uporaba
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
DK2292779T3 (en) 2003-09-30 2017-02-27 Univ Pennsylvania ADENOASS-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME AND APPLICATIONS THEREOF
PT1791858E (pt) 2004-09-24 2010-07-26 Intercell Ag PROTENA DE CáPSIDE VP1 MODIFICADA DO PARVOVRUS B19
ES2385837T3 (es) 2004-12-15 2012-08-01 The University Of North Carolina At Chapel Hill Vectores quiméricos
CN106906241B (zh) 2005-04-07 2020-09-11 宾夕法尼亚大学托管会 增强腺相关病毒载体功能的方法
WO2006119432A2 (en) 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
PT3272872T (pt) 2005-10-20 2020-06-26 Uniqure Ip Bv Vetores aav melhorados produzidos em células de insetos
WO2007089632A2 (en) 2006-01-27 2007-08-09 The University Of North Carolina At Chapel Hill Heparin and heparan sulfate binding chimeric vectors
EP2007795B1 (de) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav-capsid-proteine
EP2016174A2 (de) 2006-04-28 2009-01-21 The Trustees of the University of Pennsylvania Modifizierte aav-vektoren mit reduzierter capsid-immunogenizität und verwendung davon
US20070274985A1 (en) * 2006-05-26 2007-11-29 Stefan Dubel Antibody
WO2008124015A1 (en) 2007-04-09 2008-10-16 The Regents Of The University Of California Methods for purifying adeno-associated virus virions
PL2191001T3 (pl) 2007-04-09 2017-01-31 University Of Florida Research Foundation, Inc. Kompozycje wektora RAAV mające białka kapsydu zmodyfikowane tyrozyną i sposoby ich zastosowania
EP2012122A1 (de) 2007-07-06 2009-01-07 Medigene AG Strukturproteine von mutierten Parvoviren als Impfstoffe
US20100203083A1 (en) 2007-05-31 2010-08-12 Medigene Ag Mutated structural protein of a parvovirus
CA2693712C (en) 2007-07-14 2018-05-29 The University Of Iowa Research Foundation Methods and compositions for treating brain diseases
US20090215879A1 (en) 2008-02-26 2009-08-27 University Of North Carolina At Chapel Hill Methods and compositions for adeno-associated virus (aav) with hi loop mutations
US8632764B2 (en) 2008-04-30 2014-01-21 University Of North Carolina At Chapel Hill Directed evolution and in vivo panning of virus vectors
EP2297185A1 (de) 2008-06-17 2011-03-23 Amsterdam Molecular Therapeutics (AMT) B.V. Parvovirales capsid mit eingebauter gly-ala-wiederholungsregion
JP2010002479A (ja) 2008-06-18 2010-01-07 Crossfor:Kk メガネレンズ用装飾体およびメガネ用装飾体装着具
KR102095257B1 (ko) * 2008-06-25 2020-04-01 노바르티스 아게 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
WO2010031865A1 (en) 2008-09-19 2010-03-25 Charitē Universitätsmedizin Berlin Identification and characterisation of recombinant viral gene therapy vectors
US8889641B2 (en) 2009-02-11 2014-11-18 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
US9133479B2 (en) 2009-06-03 2015-09-15 Cedars-Sinai Medical Center Effective vector platform for gene transfer and gene therapy
US8586526B2 (en) 2010-05-17 2013-11-19 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
WO2011038187A1 (en) 2009-09-25 2011-03-31 The Trustees Of The University Of Pennsylvania Controlled adeno-associated virus (aav) diversification and libraries prepared therefrom
US8299295B2 (en) 2009-10-15 2012-10-30 Johnson Matthey Public Limited Company Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US8263396B2 (en) 2010-04-01 2012-09-11 Weidong Xiao Methods and compositions for the production of recombinant virus vectors
JP5963743B2 (ja) 2010-04-23 2016-08-03 ユニバーシティ オブ マサチューセッツ Ｃｎｓターゲティングａａｖベクターおよびその使用方法
US8628966B2 (en) 2010-04-30 2014-01-14 City Of Hope CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
US10415056B2 (en) 2010-11-10 2019-09-17 Fred Hutchinson Cancer Research Center Compositions and methods for generating adeno-associated viral vectors with undetectable capsid gene contamination
US9409953B2 (en) 2011-02-10 2016-08-09 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
WO2012112578A2 (en) 2011-02-14 2012-08-23 The Children's Hospital Of Philadelphia Improved aav8 vector with enhanced functional activity and methods of use thereof
JP6224459B2 (ja) 2011-02-17 2017-11-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組織特異性を改変し、ａａｖ９媒介遺伝子導入を改善するための組成物および方法
WO2012145601A2 (en) 2011-04-22 2012-10-26 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
KR101397088B1 (ko) * 2011-06-10 2014-05-19 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
WO2012169822A2 (ko) * 2011-06-10 2012-12-13 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
DK2748201T3 (en) 2011-08-23 2018-02-12 Roche Glycart Ag BISPECIFIC T-CELL ACTIVATING ANTIGIN BINDING MOLECULES
EP3147295B2 (de) 2011-08-24 2023-11-22 The Board of Trustees of the Leland Stanford Junior University Neue aav-capsid-proteine zum transport von nukleinsäuren
CN103874508A (zh) 2011-10-21 2014-06-18 英特维特国际股份有限公司 提供多价免疫的重组非致病性mdv载体
US20140359799A1 (en) 2011-12-23 2014-12-04 Case Western Reserve University Targeted gene modification using hybrid recombinant adeno-associated virus
CN104520428B (zh) 2012-02-17 2018-09-21 费城儿童医院 将基因转移到细胞、器官和组织的aav载体组合物和方法
RU2683497C2 (ru) 2012-04-18 2019-03-28 Дзе Чилдрен'З Хоспитал Оф Филадельфия Композиция и способы высокоэффективного переноса генов с помощью вариантов капсида aav
EP2660325A3 (de) 2012-05-02 2014-02-12 Christian Medical College AAV-Vektoren und dazugehörige Nukleotidsequenzen und Verfahren
JP6385920B2 (ja) 2012-05-09 2018-09-05 オレゴン ヘルス アンド サイエンス ユニバーシティー アデノ随伴ウイルスプラスミド及びベクター
WO2013174760A1 (en) 2012-05-25 2013-11-28 Deutsches Krebsforschungszentrum Optimized aav-vectors for high transduction rates in dendritic cells
EP2692731A1 (de) 2012-07-31 2014-02-05 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Rekombinante AAV-Vektorparitikel mit Liganden hoher Affinität für Zelltyp-spezifischen Gentransfer
CA2885544A1 (en) 2012-09-28 2014-04-03 The University Of North Carolina At Chapel Hill Aav vectors targeted to oligodendrocytes
EP2940131B1 (de) 2012-12-25 2019-02-20 Takara Bio Inc. Aav-variante
DK2954051T3 (da) 2013-02-08 2019-07-08 Univ Pennsylvania Modificeret kapsid til genoverførsel til behandling af nethinden
AU2014244167A1 (en) 2013-03-13 2015-10-08 The Children's Hospital Of Philadelphia Adeno-associated virus vectors and methods of use thereof
EP3003391B1 (de) 2013-05-31 2021-09-22 The Regents of The University of California Adenoassoziierte virenvarianten und verfahren zur verwendung davon
BR112016000546A2 (pt) * 2013-07-12 2017-11-21 Ophthotech Corp métodos para tratar ou prevenir condições oftalmológicas
CA3019426A1 (en) * 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
US11596699B2 (en) * 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
CR20180589A (es) 2016-05-13 2019-02-27 4D Molecular Therapeutics Inc Cápsulas variantes de virus adenoasociados y métodos de uso de estas
EP3795181A1 (de) * 2016-06-16 2021-03-24 Adverum Biotechnologies, Inc. Behandlung von amd mit aav2-variante mit aflibercept
CA3054942A1 (en) * 2017-03-17 2018-09-20 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression
CR20200165A (es) 2017-09-20 2020-06-05 4D Molecular Therapeutics Inc Variantes de cápsides de virus adenoasociados y métodos de uso de estas
AU2018350990A1 (en) * 2017-10-18 2020-05-21 Regenxbio Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap

Also Published As

Publication number Publication date
AU2018372235B2 (en) 2022-02-24
US11766489B2 (en) 2023-09-26
EP4272728A3 (de) 2024-06-12
JP7184894B2 (ja) 2022-12-06
US20200282077A1 (en) 2020-09-10
EP4272728A2 (de) 2023-11-08
CN111770999A (zh) 2020-10-13
RU2020121215A3 (de) 2021-12-29
EP3717636B1 (de) 2023-03-08
IL274712A (en) 2020-07-30
BR112020010674A2 (pt) 2020-11-10
AU2022203494A1 (en) 2022-06-09
EP3717636A4 (de) 2021-09-08
DK3717636T3 (da) 2023-05-30
MX2020005451A (es) 2020-08-27
JP2024015194A (ja) 2024-02-01
UA127831C2 (uk) 2024-01-17
PH12020550706A1 (en) 2021-04-26
AU2018372235A1 (en) 2020-06-11
JP2022121534A (ja) 2022-08-19
EP3717636A1 (de) 2020-10-07
EP4219695A3 (de) 2024-01-17
CL2020001360A1 (es) 2020-09-11
CA3083472A1 (en) 2019-05-31
FI3717636T3 (fi) 2023-06-01
JP2021503914A (ja) 2021-02-15
PT3717636T (pt) 2023-05-30
CR20200282A (es) 2021-02-18
RU2020121215A (ru) 2021-12-29
WO2019104279A1 (en) 2019-05-31
ES2946747T3 (es) 2023-07-25
KR20200088853A (ko) 2020-07-23
AU2018372235B9 (en) 2022-03-10
PE20210915A1 (es) 2021-05-19
EP4219695A2 (de) 2023-08-02

Similar Documents

Publication Publication Date Title
IL274712A (en) Adeno-associated virus variant capsids and use to prevent angiogenesis
ZA202001679B (en) Adeno-associated virus variant capsids and methods of use thereof
ZA201905485B (en) Adeno-associated virus variant capsids and methods of use thereof
IL279154B (en) Adenovirus-related vector
IL263801A (en) Novel adeno-associated virus capsid proteins
IL266264A (en) Adeno-associated virus formulations
HK1246355A1 (zh) 腺相關病毒變體及其使用方法
ZA201900278B (en) Variant adeno-associated viruses and methods of using
IL267949A (en) Altered virus
IL275533A (en) Adeno-associated virus purification methods
IL267785A (en) virus
SG11202009854XA (en) Modified viral capsids
ZA202002158B (en) Peptide for inhibiting angiogenesis and use thereof
GB201813175D0 (en) Virus use
GB201808500D0 (en) Virus and virus use
GB201707839D0 (en) Attenuated virus
GB201716047D0 (en) Virus
GB201700259D0 (en) Virus
GB201706600D0 (en) Virus preparations
GB201600380D0 (en) Modified virus